Key facts
- It has raised $500K; the latest was Early Stage VC ($500K) in Jan 2025.
- Notable investors include Invento Capital Partners, PMK-Group.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for CheMOnitor
- ·The full record, as it builds
Funding rounds
No funding rounds for CheMOnitor are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About CheMOnitor
Developer of a molecular diagnostic test designed to predict the effectiveness of chemotherapy at an early stage. The company combines ultra-high-resolution glycan analysis with artificial intelligence-supported data interpretation to detect ineffective chemotherapy after the first dose, support timely treatment adjustments, enabling lung cancer doctors and clinics to lower therapy and hospitalization costs, improve five-year survival rates and patient quality of life, and enhance overall healthcare system efficiency.
- Sector
- Healthcare
- HQ
- Veszprem, Hungary
- Founded
- 2025
- Website
- chemonitor.hu/
- Ownership
- Privately Held (backing)
CheMOnitor doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in CheMOnitor shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on CheMOnitor in its N-PORT filings yet. We sweep new filings monthly.